Pharmalittle: Trump to give speech today on drug pricing; FDA approves a novel, but pricey flu drug

first_img About the Author Reprints What’s included? Tags Donald Trumpdrug pricesFDAflupharmaceuticalspharmalittleSTAT+ Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Rise and shine, everyone, another busy day is on the way. This will be an especially hectic day, in fact, thanks to a flurry of news about everyone’s favorite topic — the cost of medicines. Besides a speech from President Trump, which you can read about below, we will be quarterbacking a discussion today. So time to fire up the coffee kettle and get cracking. Here is the menu of tidbits to help you get started. Hope all goes well today and you conquer the world. And, as always, do keep in touch …President Trump on Thursday will unveil a plan to overhaul how Medicare pays for certain drugs, attacking “foreign freeloaders” that he says have driven up costs in the U.S., Politico reports. The speech, which comes just days before the tightly contested midterm elections, follows two major drug-pricing headline wins, STAT notes. One is a proposal to force drug makers to include list prices in TV ads, and then there is a new law that bans so-called gag clauses, which prevent pharmacists from telling customers when it’s cheaper to pay cash for a drug rather than using insurance. [email protected] Log In | Learn More Pharmalittle: Trump to give speech today on drug pricing; FDA approves a novel, but pricey flu drug By Ed Silverman Oct. 25, 2018 Reprints Alex Hogan/STATcenter_img Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. GET STARTED What is it? Ed Silverman Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. @Pharmalot Pharmalot last_img read more